170 related articles for article (PubMed ID: 24059369)
1. Imatinib and beyond in gastrointestinal stromal tumors: A radiologist's perspective.
Tirumani SH; Jagannathan JP; Krajewski KM; Shinagare AB; Jacene H; Ramaiya NH
AJR Am J Roentgenol; 2013 Oct; 201(4):801-10. PubMed ID: 24059369
[TBL] [Abstract][Full Text] [Related]
2. Treatment response monitoring in patients with gastrointestinal stromal tumor using diffusion-weighted imaging: preliminary results in comparison with positron emission tomography/computed tomography.
Gong NJ; Wong CS; Chu YC; Gu J
NMR Biomed; 2013 Feb; 26(2):185-92. PubMed ID: 22806958
[TBL] [Abstract][Full Text] [Related]
3. NCCN Task Force report: gastrointestinal stromal tumor (GIST).
Demetri G; DeMatteo RP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-25-8. PubMed ID: 23570095
[No Abstract] [Full Text] [Related]
4. Management of gastrointestinal stromal tumor: the imatinib era and beyond.
Parikh PM; Gupta S
Indian J Cancer; 2013; 50(1):31-40. PubMed ID: 23713042
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
6. Presentation and management of gastrointestinal stromal tumours.
Mongan AM; Malik V; Rowley S; Claxton Z; Muldoon C; O'Toole D; Ravi N; Reynolds JV
Ir Med J; 2013 Jun; 106(6):176-9. PubMed ID: 23909154
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.
Lee CK; Goldstein D; Gibbs E; Joensuu H; Zalcberg J; Verweij J; Casali PG; Maki RG; Cioffi A; Mcarthur G; Lord SJ; Yip D; Kanjanapan Y; Rutkowski P
Eur J Cancer; 2015 May; 51(7):852-60. PubMed ID: 25801699
[TBL] [Abstract][Full Text] [Related]
8. Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib.
Vij M; Patra S; Rela M
Indian J Pathol Microbiol; 2013; 56(3):291-3. PubMed ID: 24152514
[TBL] [Abstract][Full Text] [Related]
9. CT scan is not everything in the evaluation of a patient with gastrointestinal tumors (GIST) under imatinib therapy.
Wang CM; Fu H; Zhao GF; Wang J; Shi YQ
Pathol Oncol Res; 2012 Oct; 18(4):1095-7. PubMed ID: 21927980
[No Abstract] [Full Text] [Related]
10. [Two cases of recurrent GIST successfully treated with imatinib mesylate at 100mg/day].
Hanada N; Kawata K; Okamura S; Tomiyama N; Hori K
Gan To Kagaku Ryoho; 2013 Jun; 40(6):803-5. PubMed ID: 23863663
[TBL] [Abstract][Full Text] [Related]
11. MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.
Gao X; Shen K; Wang C; Ling J; Wang H; Fang Y; Shi Y; Hou Y; Qin J; Sun Y; Qin X
Acta Biochim Biophys Sin (Shanghai); 2014 Jan; 46(1):72-5. PubMed ID: 24217767
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of imatinib for treatment of metastatic GIST.
Patel S
Cancer Chemother Pharmacol; 2013 Aug; 72(2):277-86. PubMed ID: 23503753
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal stromal tumour treated with neoadjuvant imatinib.
Loughrey MB; Mitchell C; Mann GB; Michael M; Waring PM
J Clin Pathol; 2005 Jul; 58(7):779-81. PubMed ID: 15976351
[TBL] [Abstract][Full Text] [Related]
14. Complete pathological response in advanced extra-gastrointestinal stromal tumor after imatinib mesylate therapy: a case report.
Rediti M; Pellegrini E; Molinara E; Cerullo C; Fonte C; Lunghi A; Iori A; Neri B
Anticancer Res; 2014 Feb; 34(2):905-7. PubMed ID: 24511030
[TBL] [Abstract][Full Text] [Related]
15. [Long-term survival in a case of recurrent gastrointestinal stromal tumor treated with intermittent or low-dose imatinib].
Kurata Y; Takaishi S; Sakuma Y; Iwasaki K; Nimura Y; Tohma T; Kagaya A; Yamamoto Y; Matsubara H
Gan To Kagaku Ryoho; 2014 Mar; 41(3):379-82. PubMed ID: 24743288
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
[TBL] [Abstract][Full Text] [Related]
17. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
Griffin JM; Amand MS; Demetri GD
Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
[TBL] [Abstract][Full Text] [Related]
18. Current directions in systemic therapy for gastrointestinal stromal tumors.
Chugh R
Curr Probl Cancer; 2011; 35(5):255-70. PubMed ID: 22118565
[No Abstract] [Full Text] [Related]
19. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
Jakob J; Mussi C; Ronellenfitsch U; Wardelmann E; Negri T; Gronchi A; Hohenberger P
Ann Surg Oncol; 2013 Feb; 20(2):586-92. PubMed ID: 22965573
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.
Shankar S; vanSonnenberg E; Desai J; Dipiro PJ; Van Den Abbeele A; Demetri GD
Radiology; 2005 Jun; 235(3):892-8. PubMed ID: 15833985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
